Description:

Study part: Subject Treatment Status (Unscheduled). A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Keywords:
Versions (1) ▾
  1. 2/20/18
Copyright Holder:
Roche
Uploaded on:

February 20, 2018

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Subject Treatment Status (Unscheduled) rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g

Subject Treatment Status (Unscheduled)

SUBJECT TREATMENT STATUS (UNSCHEDULED)